Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch Albareda, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon Kater, Vesa Lindström, Mattias Mattsson, Carsten Niemann, Philipp Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Annamaria Frustaci, Lydia Scarfo, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 1.

https://doi.org/10.1182/blood-2025-1

Published: 2025

Journal Articles

Virtual reality and hypnosis to alleviate anxiety and pain in patients undergoing bone marrow aspiration and biopsy: A randomized controlled trial

Ilana Levy Yurkovski, Dina Libes, Maya Meiseles, Natalia Kreiniz, Wesal Gara, Tamar Tadmor

Blood (2025) 146 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2025-4428

Published: 2025

Journal Articles

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Blood (2025) 146 (Supplement 1): 795.

https://doi.org/10.1182/blood-2025-795

Published: 2025

Journal Articles

Dynamic machine Learning–Based prediction of major bleeding in patients receiving anticoagulant therapy: A multi-center study

Ron Likvornik, Lior Rokach, Noam Benyamini, Anatoly Nemets, Galia Stemer, Orit Sofer, Maya Koren-Michowitz, Tamar Tadmor

Blood (2025) 146 (Supplement 1): 314.

https://doi.org/10.1182/blood-2025-314

Published: 2025

Journal Articles

Identification of red cell distribution width as a key predictor of leukemic transformation in polycythemia vera and essential thrombocythemia: A machine learning approach involving 10,560 cases

Lior Rokach, Tamar Tadmor, Rania Abdelaziz, Guy Melamed, Priyansh Faldu, Hilel Alapi, Muhammad Yousuf, Merry Nakhleh, Animesh Pardanani, Kaaren Reichard, Rong He, Naseema Gangat, Ayalew Tefferi

Blood (2025) 146 (Supplement 1): 2021.

https://doi.org/10.1182/blood-2025-2021

Published: 2025

Journal Articles

Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study

Blood (2025) 146 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2025-2750

Published: 2025

Journal Articles

Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study

Blood (2025) 146 (Supplement 1): 3893.

https://doi.org/10.1182/blood-2025-3893

Published: 2025

Journal Articles

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Philip Thompson, Tamar Tadmor, Hans Herluf Bentzen, Raul Cordoba, Sylvia Snauwaert, Neta Goldschmidt, Martin Simkovic, Jacob Christensen, Javier Lopez Jimenez, Ohad Benjamini, Toshihiko Oki, Andrew J. Steele, Marie Holst Mørch, Ernestine Tucker, Rebecca Valentin, Alexey Danilov, Umberto Vitolo

Blood (2025) 146 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2025-1015

Published: 2025

Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Blood (2025) 146 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2025-3903

Published: 2025

Journal Articles

Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: A multicenter retrospective study

Blood (2025) 146 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2025-3618

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Blood (2024) 144 (Supplement 1): 4626.

https://doi.org/10.1182/blood-2024-204852

Published: 2024

Journal Articles

Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Tamar Tadmor, Toby A. Eyre, Ohad Benjamini, Arvind Chaudhry, Juan Shen, Siyang Leng, Mohammed Z. H. Farooqui, David Lavie

Blood (2024) 144 (Supplement 1): 1875.2.

https://doi.org/10.1182/blood-2024-198731

Published: 2024

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Shlomzion Aumann, Abraham Avigdor, Ronit Marcus, Netanel A. Horowitz, Ronit Gurion, Tamar Tadmor, Roy Vitkon, May Meira Basood, Uri Abadi, Meirav Kedmi

Blood (2024) 144 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2024-198926

Published: 2024

Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Blood (2024) 144 (Supplement 1): 883.

https://doi.org/10.1182/blood-2024-199708

Published: 2024

Journal Articles

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz, Osnat Bairey, Reut Harel, Nadav Sarid, Tsofia Levi, Ofir Wolach, Yair Herishanu

Blood (2024) 144 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2024-205236

Published: 2024

Journal Articles

Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Blood (2024) 144 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2024-204797

Published: 2024

Journal Articles

Development of a Machine Learning-Based Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating BTK Inhibitor Therapy

Tamar Tadmor, Guy Melamed, Hilel Alapi, Sivan Gazit, Tal Patalon, Lior Rokach

Blood (2024) 144 (Supplement 1): 3239.

https://doi.org/10.1182/blood-2024-194723

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Virtual reality and hypnosis to alleviate anxiety and pain in patients undergoing bone marrow aspiration and biopsy: A randomized controlled trial

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Dynamic machine Learning–Based prediction of major bleeding in patients receiving anticoagulant therapy: A multi-center study

Identification of red cell distribution width as a key predictor of leukemic transformation in polycythemia vera and essential thrombocythemia: A machine learning approach involving 10,560 cases

Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study

Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: A multicenter retrospective study

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Development of a Machine Learning-Based Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating BTK Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only